Nephrology Doctors in Lynchburg, VA Accepting Medicare

8 Nephrology doctors found. Showing 1 - 8

Sasmit Roy, MD Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 2091 Langhorne Rd, Lynchburg, VA 24501 Phone: 434-947-3954

Nyein Chann Wai Lynn, Internal Medicine - Nephrology Medicare: Medicare Enrolled Practice Location: 2091 Langhorne Rd, Lynchburg, VA 24501 Phone: 434-947-3954    Fax: 877-583-4046

Waqas Memon, Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 103 Clifton Street, Lynchburg, VA 24501 Phone: 703-943-8086

Dr. Mohammed Khairul Ashraf, M.D. Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 2091 Langhorne Rd, Lynchburg, VA 24501 Phone: 434-947-3954    Fax: 434-455-5947

Dr. Samuel Dadzie, M.D Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1901 Tate Springs Rd, Lynchburg, VA 24501 Phone: 434-200-2925    Fax: 434-200-3650

Jagan Kothapally, M.D. Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 2091 Langhorne Rd, Lynchburg, VA 24501 Phone: 434-947-3954    Fax: 434-947-5944

Xiaoru Yang, M.D. Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1901 Tate Springs Rd, Lynchburg, VA 24501 Phone: 434-200-5895    Fax: 434-200-7529

Dr. Thurein Kyaw, M.D Internal Medicine - Nephrology Medicare: Accepting Medicare Assignments Practice Location: 2091 Langhorne Rd, Lynchburg, VA 24501 Phone: 434-947-3954    Fax: 434-455-5947

News Archive

Nektar reports positive results from NKTR-102 Phase 2 study in metastatic breast cancer at CTRC-AACR SABCS

Nektar Therapeutics today announced positive results from a Phase 2 clinical study evaluating single-agent NKTR-102 in patients with metastatic breast cancer during the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS). NKTR-102, a novel investigational topoisomerase I inhibitor-polymer conjugate, is Nektar's lead oncology candidate and is being evaluated in multiple cancer indications.

Gene-editing technology enhances T cell immunotherapies for treating cancer

Last year, the Food and Drug Administration approved the first cellular immunotherapies to treat cancer. These therapies involve collecting a patient's own immune cells - called T cells - and supercharging them to home in on and attack specific blood cancers, such as hard-to-treat acute lymphoblastic leukemia and non-Hodgkin lymphoma.

M-3 Information introduces iPhone application for depression, anxiety disorders

M-3 Information entered the smart phone application environment by offering the M-3 Checklist, a scientifically validated screen for depression and anxiety disorders, at the iTunes store on Friday, April 30, 2010. Adapted from M-3 Information's existing mymoodmonitor.com website, this mobile version, called mym3, provides the same validated mental health questionnaire optimized for smart phones. A first in iPhone applications, mym3 is designed to create a bridge between user responses and recommendations set forth in the content-rich M3 website application.

Drexel scientists identify how two new antimalarial drugs work

Drexel University scientists have discovered an unusual mechanism for how two new antimalarial drugs operate: They give the parasite's skin a boost in cholesterol, making it unable to traverse the narrow labyrinths of the human bloodstream.

Read more Medical News

› Verified 8 days ago